Announcements, conference presence and publications are posted first on our company page.
InterAx Biotech and Alveus Therapeutics announced a strategic research collaboration and licensing agreement, signed on 2 June 2025, to develop a differentiated small-molecule candidate for metabolic disease. The agreement includes an upfront payment and eligibility for development, regulatory and commercial milestones. Alveus was founded by former Novo Nordisk and Eli Lilly executives.
Andrew Roberts joined InterAx as CEO to lead the company's transition from a drug discovery technology pioneer to a developer of differentiated GPCR drug candidates. He brings more than 20 years of biopharmaceutical R&D and portfolio leadership at Novartis, Sandoz and Biogen Idec, and was Chief Portfolio Officer at Alvotech.
InterAx was selected as a participant in a Horizon Europe EIC Pathfinder project developing new methods to characterize the intracellular effects of drug candidates. The reviewers recognized the company's use of mathematical models and machine learning to design drugs with targeted cellular effects.
Dr Mark Levick, former CEO of Alvotech and former Senior Vice President of Global Drug Discovery at Novartis, joined the InterAx board. He oversaw R&D programs that resulted in thirteen drug approvals, five of them first-in-class, and advises the company as it advances its pipeline toward clinical trials.